PLETHICO PHARMA = RESULTS FOR = CY 2010-2009-2008 = GOOD PROGRES

Plethico Pharmaceuticals Limited

NSE Symbol PLETHICO

CONSOLIDATED RESULTS FOR CY 2010

Plethico Pharma has declared its consolidated results for the Calendar year 2010. These are compared below with the years 2009 and 2008.

Net Sales for CY 2010 I Rs.1518.12 cr – higher by 22.13% from CY 2009 and by 582.57% from CY 2008. The sales have grown in a healthy fashion over the last 2 previous years.

Total Expenditure for CY 2010 is Rs.1233.20 cr – higher by 20.37% from CY 2009 and by 524.76% from CY 2008.

Profit from Operations is Rs.284.92 Cr – up by 30.33% from CY 2009 and by a huge 1038.56% from CY 2008.

Profit before tax is Rs.255.53 for CY 2010 – up by 31.72% from CY 2009 and by 656.8% from CY 2008.

Consolidated Net Profit is Rs.244.39 cr – up by 12.67% from CY 2009  and up by over 2305% from CY 2008.

Basic EPS Before  Extraordinary Items is Rs.67.72 in CY 2010 – against Rs.58.88 in CY2009; and Rs.16.78 in CY 2008.

Thus, over all, the Consolidated results appear to be quite Good.

RESULTS  TABLE :

Plethico Pharma-Consol	JAN – DEC 10	JAN-DEC09	JAN-DEC08
Net Sales	151812	124307.5	22241.26
Net Sales	151812	22.13	582.57
Incr./Decr. in SIT / WIP	-2734.2	-1758.65	-522.25
Raw Materials	37538.9	30094.15	7070.98
Traded goods	39065.9	27137.75	1767.26
Employees Cost	11730.6	11013.08	2687.53
Depreciation	2836	1855.32	910.26
Other Expenditure	34882.6	34105.27	7825.04
Total Expenditure	123320	102446.92	19738.82
Total Expenditure	123320	20.37	524.76
Profit from Operations	28491.7	21860.58	2502.44
Profit from Operations	28491.7	30.33	1038.56
Other Income	116.1	544.64	1735.13
Interest	3054.6	3005.24	861.07
Profit before tax	25553.2	19399.98	3376.5
Profit before tax	25553.2	31.72	656.8
Tax Expense	2482.2	-657.24	-2340.34
Net Profit after tax	23071	20057.22	5716.84
Extraordinary Items	-1368.8	-1635	6825
Net Profit	24439.8	21692.22	-1108.16
Consolidated Net Profit	24439.8	21692.22	-1108.16
Consolidated Net Profit	24439.8	12.67	2305.44
Face Value (in Rs.)	10	10	10
Paid-up Equity	3407.67	3406.67	3406.67
Basic EPS B EI	67.72	58.88	16.78
Diluted EPS B EI	57.48	49.97	16.78
Basic EPS after EI	71.74	63.68	-3.25
Diluted EPS after EI	60.89	54.04	-3.25
Public Holding (%)	12.99	12.99	12.99

ANNOUNCEMENTS

TO NSE

31-03-2011          on March 31, 2011 recommended dividend @ 25 % i.e. Rs. 2.50 per equity share of the Company.

15-02-2011          Board of Directors of the Company has, at its meetings held on February 14, 2011 considered the following: (1) Allotment of 20,00,000 warrants at a price of Rs.400/- per warrant, convertible into equity shares of Rs.10/- each fully paid up at a premium of Rs.390/- per share on a preferential allotment basis, to M/s Arum Investments Private Limited. (2) Approval of Statement of Advertisement under section 58A of the Companies Act, 1956 for acceptance of Deposits.

14-02-2011          "Medical Research Institute (MRI) Appoints Fitness Competitor/Trainer Kyle Clarke as an Athlete Spokesperson for the Brand".

13-11-2010          "Plethico Pharmaceuticals Limited has received the approval for GMP clearance from the 

Therapeutic Goods Administration (TGA), Department of Health and Ageing, Australian Government for Company's manufacturing unit situated at Indore-Ahmedabad Road, NH 59 Village Dharavara, Post Kalaria, Indore (M.P.)".

26-08-2010          "MRI and Prolab to Feature MMA Fighters, Prize Raffles, and Product Samples at Boston UFC Fan Expo, in Partnership with FIGHT! Magazine".

28-06-2010          "Walmart Stores to Provide Natrol on Shelf with Vitamins in U.S.".

26-05-2010          the Company has received the Certificate of GMP Compliances of a Manufacturer issued by Medicines and Healthcare Products Regulatory Agency(MHRA), U.K. for complying with the principles and guidelines of Good Manufacturing Practice for Capsules- Hard shell, Tablets.

 *   *   *    E   N   D   *   *   *